{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:27:22Z","timestamp":1778758042707,"version":"3.51.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40123-026-01365-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:30:35Z","timestamp":1775755835000},"page":"1585-1622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Management of Polypoidal Choroidal Vasculopathy: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Adrian","family":"Koh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios D.","family":"Panos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taffeta Ching Ning","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1545-6199","authenticated-orcid":false,"given":"Theo","family":"Empeslidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"4","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/archopht.1997.01100150480005","volume":"115","author":"LA Yannuzzi","year":"1997","unstructured":"Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115(4):478\u201385.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1365_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1\u20138.","journal-title":"Retina"},{"issue":"4","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/archopht.120.4.502","volume":"120","author":"RH Rosa Jr","year":"2002","unstructured":"Rosa RH Jr, Davis JL, Eifrig CWG. Clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 2002;120(4):502\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1365_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100144","volume":"14","author":"P Ruamviboonsuk","year":"2025","unstructured":"Ruamviboonsuk P, Ng DSC, Chaikitmongkol V, et\u00a0al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS). Asia Pac J Ophthalmol (Phila). 2025;14(1):100144.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"3","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, et\u00a0al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV workgroup. Ophthalmology. 2021;128(3):443\u201352.","journal-title":"Ophthalmology"},{"issue":"21","key":"1365_CR6","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.3390\/jcm11216274","volume":"11","author":"M Sasaki","year":"2022","unstructured":"Sasaki M, Kawasaki R, Yanagi Y. Early stages of age-related macular degeneration: racial\/ethnic differences and proposal of a new classification incorporating emerging concept of choroidal pathology. J Clin Med. 2022;11(21):6274.","journal-title":"J Clin Med"},{"key":"1365_CR7","doi-asserted-by":"publisher","first-page":"1637377","DOI":"10.1155\/2021\/1637377","volume":"2021","author":"G Azar","year":"2021","unstructured":"Azar G, Vasseur V, Lahoud C, et\u00a0al. Polypoidal choroidal vasculopathy diagnosis and neovascular activity evaluation using optical coherence tomography angiography. Biomed Res Int. 2021;2021:1637377.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000355488","volume":"231","author":"S Honda","year":"2014","unstructured":"Honda S, Matsumiya W, Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition. Ophthalmologica. 2014;231(2):59\u201374.","journal-title":"Ophthalmologica"},{"issue":"16","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.3390\/jcm11164766","volume":"11","author":"EHC van Dijk","year":"2022","unstructured":"van Dijk EHC, Holtz JK, Sirks MJ, et\u00a0al. European prevalence of polypoidal choroidal vasculopathy: a systematic review, meta-analysis, and forecasting study. J Clin Med. 2022;11(16):4766.","journal-title":"J Clin Med"},{"issue":"5","key":"1365_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/jcm4050782","volume":"4","author":"CW Wong","year":"2015","unstructured":"Wong CW, Wong TY, Cheung CM. Polypoidal choroidal vasculopathy in Asians. J Clin Med. 2015;4(5):782\u2013821.","journal-title":"J Clin Med"},{"issue":"12","key":"1365_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261320","volume":"16","author":"M Saito","year":"2021","unstructured":"Saito M, Iida T, Saito K, et\u00a0al. Long-term characteristics of exudative age-related macular degeneration in Japanese patients. PLoS ONE. 2021;16(12):e0261320.","journal-title":"PLoS One"},{"key":"1365_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OPTH.S385827","volume":"17","author":"P Sen","year":"2023","unstructured":"Sen P, Manayath G, Shroff D, Salloju V, Dhar P. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol. 2023;17:53\u201370.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1365_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","volume":"39","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Dansingani KK, Koizumi H, et\u00a0al. Pachychoroid disease: review and update. Eye. 2025;39(5):819\u201334.","journal-title":"Eye"},{"issue":"1","key":"1365_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31649-x","volume":"13","author":"H Fukuyama","year":"2023","unstructured":"Fukuyama H, BouGhanem G, Moir J, Skondra D, Gomi F, Fawzi AA. Clinical variations of polypoidal choroidal vasculopathy: a cohort study from Japan and the USA. Sci Rep. 2023;13(1):4800.","journal-title":"Sci Rep"},{"key":"1365_CR15","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2147\/OPTH.S47511","volume":"7","author":"T Oluleye","year":"2013","unstructured":"Oluleye T, Babalola Y. Pattern of presentation of idiopathic polypoidal choroidal vasculopathy in Ibadan, Sub-Saharan Africa. Clin Ophthalmol. 2013;7:1373\u20136.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"1365_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.oret.2025.04.019","volume":"9","author":"MJ Sirks","year":"2025","unstructured":"Sirks MJ, van Dijk EHC, Ghalayini H, et\u00a0al. The clinical spectrum of polypoidal choroidal vasculopathy in white patients: a retrospective multicenter cohort study. Ophthalmol Retina. 2025;9(10):994\u20131004.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"1365_CR17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41433-018-0168-2","volume":"32","author":"EI Agorogiannis","year":"2018","unstructured":"Agorogiannis EI, Pearce IA, Yadav S, Parry DG, Beare NAV. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy. Eye (Lond). 2018;32(11):1731\u20139.","journal-title":"Eye (Lond)"},{"issue":"2","key":"1365_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00417-020-04844-z","volume":"259","author":"EHC van Dijk","year":"2021","unstructured":"van Dijk EHC, Mohabati D, Veselinovic S, Chung WH, Dijkman G, Boon CJF. The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. Graefes Arch Clin Exp Ophthalmol. 2021;259(2):351\u201361.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1365_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(5):624\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1365_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101680","volume":"13","author":"J Zhao","year":"2023","unstructured":"Zhao J, Chandrasekaran PR, Cheong KX, Wong M, Teo K. New concepts for the diagnosis of polypoidal choroidal vasculopathy. Diagnostics (Basel). 2023;13(10):1680.","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"1365_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3341\/kjo.2023.0085","volume":"37","author":"S Park","year":"2023","unstructured":"Park S, Lee J, Park JB, et\u00a0al. Diagnosing polypoidal choroidal vasculopathy using color fundus photography, optical coherence tomography, and optical coherence tomography angiography. Korean J Ophthalmol. 2023;37(6):468\u201376.","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/IAE.0000000000002902","volume":"41","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Tan CS, Patalauskaite R, Margaron P, Lai TYY. Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: predictors of visual and anatomical response in the EVEREST II study. Retina. 2021;41(2):387\u201392.","journal-title":"Retina"},{"issue":"2","key":"1365_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","volume":"36","author":"BJ Fenner","year":"2022","unstructured":"Fenner BJ, Cheung CMG, Sim SS, et\u00a0al. Evolving treatment paradigms for PCV. Eye (Lond). 2022;36(2):257\u201365.","journal-title":"Eye (Lond)"},{"issue":"12","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.4103\/ijo.IJO_975_18","volume":"66","author":"CPS Ho","year":"2018","unstructured":"Ho CPS, Lai TYY. Current management strategy of polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2018;66(12):1727\u201335.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1365_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12886-019-1245-4","volume":"19","author":"J Yang","year":"2019","unstructured":"Yang J, Yuan M, Wang E, Xia S, Chen Y. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study. BMC Ophthalmol. 2019;19(1):237.","journal-title":"BMC Ophthalmol"},{"key":"1365_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2021.102453","volume":"35","author":"W Kikushima","year":"2021","unstructured":"Kikushima W, Sakurada Y, Yoneyama S, et\u00a0al. Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy. Photodiagnosis Photodyn Ther. 2021;35:102453.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"4","key":"1365_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","volume":"38","author":"CMG Cheung","year":"2024","unstructured":"Cheung CMG. Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management. Eye (Lond). 2024;38(4):659\u201367.","journal-title":"Eye (Lond)"},{"issue":"11","key":"1365_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","volume":"117","author":"LA Yannuzzi","year":"1999","unstructured":"Yannuzzi LA, Wong DWK, Sforzolini BS, et\u00a0al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117(11):1503\u201310.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1365_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjophthalmol-2015-307055","volume":"100","author":"FP Lim","year":"2016","unstructured":"Lim FP, Wong CW, Loh BK, et\u00a0al. Prevalence and clinical correlates of focal choroidal excavation in eyes with age-related macular degeneration, polypoidal choroidal vasculopathy and central serous chorioretinopathy. Br J Ophthalmol. 2016;100(7):918\u201323.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1365_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s40135-019-00201-4","volume":"7","author":"R Goldhardt","year":"2019","unstructured":"Goldhardt R, Rosen BS. Polypoidal choroidal vasculopathy. Curr Ophthalmol Rep. 2019;7(1):66\u201372.","journal-title":"Curr Ophthalmol Rep"},{"issue":"5","key":"1365_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","volume":"133","author":"M Uyama","year":"2002","unstructured":"Uyama M, Wada M, Nagai Y, et\u00a0al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133(5):639\u201348.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1365_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41598-018-37384-y","volume":"9","author":"C-H Huang","year":"2019","unstructured":"Huang C-H, Yeh P-T, Hsieh Y-T, Ho T-C, Yang C-M, Yang C-H. Characterizing branching vascular network morphology in polypoidal choroidal vasculopathy by optical coherence tomography angiography. Sci Rep. 2019;9(1):595.","journal-title":"Sci Rep"},{"issue":"14","key":"1365_CR33","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/diagnostics13142458","volume":"13","author":"X Gu","year":"2023","unstructured":"Gu X, Zhao X, Zhao Q, Wang Y, Chen Y. Recent advances in imaging polypoidal choroidal vasculopathy with swept-source optical coherence tomography angiography. Diagnostics. 2023;13(14):2458.","journal-title":"Diagnostics"},{"issue":"9","key":"1365_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/bjo.2006.112318","volume":"91","author":"H Tamura","year":"2007","unstructured":"Tamura H, Tsujikawa A, Otani A, et\u00a0al. Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography. Br J Ophthalmol. 2007;91(9):1152\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1365_CR35","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/IAE.0000000000000206","volume":"34","author":"SJ Davis","year":"2014","unstructured":"Davis SJ, Lauer AK, Flaxel CJ. Polypoidal choroidal vasculopathy in White patients. Retina. 2014;34(11):2185\u201391.","journal-title":"Retina"},{"issue":"2","key":"1365_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10384-017-0554-5","volume":"62","author":"Y Akagi-Kurashige","year":"2018","unstructured":"Akagi-Kurashige Y, Tsujikawa A, Yuzawa M, et\u00a0al. A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. Jpn J Ophthalmol. 2018;62(2):137\u201343.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"1365_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, et\u00a0al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364.","journal-title":"Retina"},{"issue":"9","key":"1365_CR38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, et\u00a0al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u201342.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1365_CR39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","volume":"158","author":"G De Salvo","year":"2014","unstructured":"De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2014;158(6):1228-38.e1.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1365_CR40","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","volume":"66","author":"G Anantharaman","year":"2018","unstructured":"Anantharaman G, Sheth J, Bhende M, et\u00a0al. Polypoidal choroidal vasculopathy: pearls in diagnosis and management. Indian J Ophthalmol. 2018;66(7):896\u2013908.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"1365_CR41","doi-asserted-by":"publisher","first-page":"e1579","DOI":"10.1111\/aos.15149","volume":"100","author":"JY Park","year":"2022","unstructured":"Park JY, Park YJ, Park SJ, et\u00a0al. Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up. Acta Ophthalmol. 2022;100(8):e1579\u201388.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1365_CR42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","volume":"103","author":"N Miyamoto","year":"2019","unstructured":"Miyamoto N, Mandai M, Oishi A, et\u00a0al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2019;103(6):844\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1365_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","volume":"155","author":"HM Kang","year":"2013","unstructured":"Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155(3):438\u201347.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1365_CR44","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s12325-022-02162-w","volume":"39","author":"AA Okada","year":"2022","unstructured":"Okada AA, Takahashi K, Ohji M, Moon SC, Machewitz T, Sasaki K. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in the ALTAIR study: 96-week outcomes in the polypoidal choroidal vasculopathy subgroup. Adv Ther. 2022;39(6):2984\u201398.","journal-title":"Adv Ther"},{"issue":"1","key":"1365_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000518235","volume":"245","author":"R Silva","year":"2022","unstructured":"Silva R, Arias L, Nunes S, et\u00a0al. Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: a randomized clinical trial. Ophthalmologica. 2022;245(1):80\u201390.","journal-title":"Ophthalmologica"},{"issue":"7","key":"1365_CR46","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, et\u00a0al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1365_CR47","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1111\/aos.15272","volume":"101","author":"X Li","year":"2023","unstructured":"Li X, Qu J, Su G, Yu S, Zhang Y, Sadda SV. The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study. Acta Ophthalmol. 2023;101(3):e327\u201337.","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"1365_CR48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/08820538.2021.1900289","volume":"36","author":"S Li","year":"2021","unstructured":"Li S, Deng X, Chen Q, Lin H, Zhang J. Characteristics of preferred retinal locus in eyes with central vision loss secondary to different macular lesions. Semin Ophthalmol. 2021;36(8):734\u201341.","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"1365_CR49","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, et\u00a0al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan study. Retina. 2015;35(8):1569\u201376.","journal-title":"Retina"},{"issue":"4","key":"1365_CR50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, et\u00a0al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013;156(4):644\u201351.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1365_CR51","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","volume":"121","author":"A Oishi","year":"2014","unstructured":"Oishi A, Miyamoto N, Mandai M, et\u00a0al. LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology. 2014;121(5):1151\u20132.","journal-title":"Ophthalmology"},{"issue":"3","key":"1365_CR52","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1111\/aos.14588","volume":"99","author":"X Li","year":"2021","unstructured":"Li X, Zhu Q, Egger A, et\u00a0al. Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. Acta Ophthalmol. 2021;99(3):e336\u201345.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"1365_CR53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, et\u00a0al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1365_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.24920\/004213","volume":"38","author":"YX Chen","year":"2023","unstructured":"Chen YX, Zhang YQ, Chen CZ, et\u00a0al. Chinese guideline on the management of polypoidal choroidal vasculopathy (2022). Chin Med Sci J. 2023;38(2):77\u201393.","journal-title":"Chin Med Sci J"},{"issue":"6","key":"1365_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, et\u00a0al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol (Phila). 2021;10(6):507\u201318.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"5","key":"1365_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","volume":"103","author":"M Miyata","year":"2019","unstructured":"Miyata M, Ooto S, Yamashiro K, et\u00a0al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2019;103(5):617\u201322.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1365_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051098","volume":"10","author":"W Kikushima","year":"2021","unstructured":"Kikushima W, Sakurada Y, Sugiyama A, et\u00a0al. Five-year outcome of aflibercept monotherapy for exudative age-related macular degeneration with good baseline visual acuity. J Clin Med. 2021;10(5):1098.","journal-title":"J Clin Med"},{"issue":"1","key":"1365_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03264-x","volume":"23","author":"J Lee","year":"2023","unstructured":"Lee J, Kim K, Kim ES, Yu S-Y, Kang MS. Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression. BMC Ophthalmol. 2023;23(1):511.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"1365_CR59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40123-024-00888-0","volume":"13","author":"KYC Teo","year":"2024","unstructured":"Teo KYC, Park K-H, Ngah NF, et\u00a0al. Six-year outcomes in subjects with polypoidal choroidal vasculopathy in the EVEREST II study. Ophthalmol Ther. 2024;13(4):935\u201354.","journal-title":"Ophthalmol Ther"},{"key":"1365_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1609717","volume":"2019","author":"J Yang","year":"2019","unstructured":"Yang J, Yuan M, Xia S, Chen Y. Six-year real-world outcomes of antivascular endothelial growth factor monotherapy and combination therapy for various subtypes of polypoidal choroidal vasculopathy. J Ophthalmol. 2019;2019:1609717.","journal-title":"J Ophthalmol"},{"issue":"1","key":"1365_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00417-021-05190-4","volume":"260","author":"HC Roh","year":"2022","unstructured":"Roh HC, Kim SJ, Kang SW, Eun JS, Choi KJ. Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):83\u201392.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1365_CR62","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1111\/aos.15015","volume":"100","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Miyata M, Ooto S, et\u00a0al. Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy. Acta Ophthalmol. 2022;100(4):e943\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"1365_CR63","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/jop.2021.0051","volume":"37","author":"JH Kim","year":"2021","unstructured":"Kim JH, Kim JW, Kim CG. Five-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther. 2021;37(9):525\u201333.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"1365_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00904-4","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim JY, Son WY, Kim RY, Kim M, Park YG, Park YH. Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. Sci Rep. 2021;11(1):21572.","journal-title":"Sci Rep"},{"issue":"2","key":"1365_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229231","volume":"15","author":"K Wataru","year":"2020","unstructured":"Wataru K, Sugiyama A, Yoneyama S, et\u00a0al. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS ONE. 2020;15(2):e0229231.","journal-title":"PLoS One"},{"issue":"2","key":"1365_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00417-013-2433-1","volume":"252","author":"M Saito","year":"2014","unstructured":"Saito M, Iida T, Kano M, Itagaki K. Five-year results of photodynamic therapy with and without supplementary antivascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2014;252(2):227\u201335.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1365_CR67","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-013-0237-9","volume":"57","author":"A Miki","year":"2013","unstructured":"Miki A, Honda S, Kojima H, et\u00a0al. Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up. Jpn J Ophthalmol. 2013;57(3):301\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1365_CR68","first-page":"615","volume":"7","author":"T Tsuchihashi","year":"2013","unstructured":"Tsuchihashi T, Mori K, Ueyama K, Yoneya S. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:615\u201320.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"1365_CR69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","volume":"135","author":"RW Beck","year":"2003","unstructured":"Beck RW, Moke PS, Turpin AH, et\u00a0al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol. Am J Ophthalmol. 2003;135(2):194\u2013205.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1365_CR70","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41433-021-01856-9","volume":"36","author":"J Chay","year":"2022","unstructured":"Chay J, Fenner BJ, Finkelstein EA, Teo KYC, Cheung CMG. Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy. Eye (Lond). 2022;36(12):2265\u201370.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1365_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52448-y","volume":"14","author":"K Sayanagi","year":"2024","unstructured":"Sayanagi K, Fujimoto S, Hara C, et\u00a0al. Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept. Sci Rep. 2024;14(1):1833.","journal-title":"Sci Rep"},{"issue":"1","key":"1365_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0237-x","volume":"16","author":"T Hikichi","year":"2016","unstructured":"Hikichi T, Kitamei H, Shioya S. Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy. BMC Ophthalmol. 2016;16(1):55.","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"1365_CR73","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1097\/IAE.0000000000001845","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim YJ. Morphologic features associated with fibrotic scarring after anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Retina. 2018;38(11):2168\u201376.","journal-title":"Retina"},{"key":"1365_CR74","unstructured":"Chawla H, Blair K, Vohra V. Polypoidal choroidal vasculopathy. [Updated 2023 Mar 16]. 2023. https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK567780\/. Accessed 17 Nov 2025."},{"issue":"8","key":"1365_CR75","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim H, Lee SC, Kwon KY, et\u00a0al. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1497\u2013503.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1365_CR76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcjo.2021.09.008","volume":"58","author":"M Jim\u00e9nez-Santos","year":"2023","unstructured":"Jim\u00e9nez-Santos M, Saenz-Franc\u00e9s F, Calvo-Gonz\u00e1lez C, Fern\u00e1ndez-Vigo JI, Donate-Lopez J, L\u00f3pez-Guajardo L. Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Can J Ophthalmol. 2023;58(2):82\u20139.","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"1365_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100082","volume":"2","author":"CS Tan","year":"2022","unstructured":"Tan CS, Lim LW, Margaron P. Evolution of polypoidal lesions after treatment of polypoidal choroidal vasculopathy. Ophthalmol Sci. 2022;2(1):100082.","journal-title":"Ophthalmol Sci"},{"issue":"3","key":"1365_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/jamaophthalmol.2019.5628","volume":"138","author":"B Doble","year":"2020","unstructured":"Doble B, Finkelstein EA, Tian Y, et\u00a0al. Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2020;138(3):251\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"1365_CR79","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2147\/OPTH.S303884","volume":"15","author":"M Sagong","year":"2021","unstructured":"Sagong M, Woo SJ, Lee Y. Real-world effectiveness, treatment pattern, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration: subgroup analyses from the LUMINOUS study. Clin Ophthalmol. 2021;15:1995\u20132011.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1365_CR80","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1038\/s41598-020-64301-z","volume":"10","author":"S Yoneyama","year":"2020","unstructured":"Yoneyama S, Sakurada Y, Kikushima W, et\u00a0al. Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2020;10(1):7188.","journal-title":"Sci Rep"},{"issue":"1","key":"1365_CR81","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1038\/s41598-019-48494-6","volume":"9","author":"Y Fukuda","year":"2019","unstructured":"Fukuda Y, Sakurada Y, Yoneyama S, et\u00a0al. Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration. Sci Rep. 2019;9(1):11906.","journal-title":"Sci Rep"},{"issue":"3","key":"1365_CR82","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1111\/aos.14960","volume":"100","author":"KL Kim","year":"2022","unstructured":"Kim KL, Joo K, Park SJ, Park KH, Woo SJ. Progression from intermediate to neovascular age-related macular degeneration according to drusen subtypes: Bundang AMD cohort study report 3. Acta Ophthalmol. 2022;100(3):e710\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"15","key":"1365_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158353","volume":"23","author":"YH Kim","year":"2022","unstructured":"Kim YH, Chung YR, Kim C, Lee K, Lee WK. The association of pachydrusen characteristics with choroidal thickness and patient\u2019s age in polypoidal choroidal vasculopathy versus central serous chorioretinopathy. Int J Mol Sci. 2022;23(15):8353.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1365_CR84","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1111\/j.1755-3768.2009.01850.x","volume":"88","author":"A Okubo","year":"2010","unstructured":"Okubo A, Arimura N, Abematsu N, Sakamoto T. Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long-term observation of non-treated eyes. Acta Ophthalmol. 2010;88(4):e107\u201314.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1365_CR85","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652\u201360.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1365_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000439445","volume":"235","author":"CR Clemens","year":"2016","unstructured":"Clemens CR, Eter N. Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring. Ophthalmologica. 2016;235(1):1\u20139.","journal-title":"Ophthalmologica"},{"issue":"2","key":"1365_CR87","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/IAE.0000000000003666","volume":"43","author":"KYC Teo","year":"2023","unstructured":"Teo KYC, Vyas C, Sun C, Cheong KX, Chakravarthy U. Five-year incidence of fellow eye neovascular involvement in age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Retina. 2023;43(2):294\u2013302.","journal-title":"Retina"},{"issue":"3","key":"1365_CR88","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5301\/ejo.5000388","volume":"24","author":"F Giansanti","year":"2014","unstructured":"Giansanti F, Bacherini D, Giacomelli G, et\u00a0al. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol. 2014;24(3):402\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"1365_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000180","volume":"2","author":"JCN Chan","year":"2017","unstructured":"Chan JCN, Chan ATC. Biologics and biosimilars: what, why and how? ESMO Open. 2017;2:e000180.","journal-title":"ESMO Open"},{"issue":"3","key":"1365_CR90","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1634\/theoncologist.2017-0126","volume":"23","author":"F Farhat","year":"2018","unstructured":"Farhat F, Torres A, Park W, et\u00a0al. The concept of biosimilars: from characterization to evolution\u2014a narrative review. Oncologist. 2018;23(3):346\u201352.","journal-title":"Oncologist"},{"key":"1365_CR91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2147\/DDDT.S457303","volume":"18","author":"E Chatzimichail","year":"2024","unstructured":"Chatzimichail E, Pfau K, Gatzioufas Z, Panos GD. Ranibizumab biosimilars in treating retinal disorders: a cost-effective revolution? Drug Des Devel Ther. 2024;18:365\u201374.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1365_CR92","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2024.02.012","volume":"8","author":"R Karkhaneh","year":"2024","unstructured":"Karkhaneh R, Faghihi H, Riazi-Esfahani H, et\u00a0al. Evaluating the efficacy and safety of aflibercept biosimilar (P041) compared to originator product in patients with neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8(8):744\u201353.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"1365_CR93","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40123-024-00914-1","volume":"13","author":"N Seo","year":"2024","unstructured":"Seo N, Guan X, Wang T, et\u00a0al. Analytical and functional similarity of aflibercept biosimilar ABP 938 with aflibercept reference product. Ophthalmol Ther. 2024;13(5):1303\u201320.","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"1365_CR94","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, et\u00a0al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023;141(7):668\u201376.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"1365_CR95","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","volume":"34","author":"AH Ross","year":"2020","unstructured":"Ross AH, Downey L, Devonport H, et\u00a0al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond). 2020;34(10):1825\u201334.","journal-title":"Eye (Lond)"},{"issue":"9","key":"1365_CR96","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, et\u00a0al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021;41(9):1911\u201320.","journal-title":"Retina"},{"key":"1365_CR97","unstructured":"Genentech to reintroduce Susvimo for people with wet age-related macular degeneration (AMD). 2024. https:\/\/www.gene.com\/media\/press-releases\/15031\/2024-07-08\/genentech-to-reintroduce-susvimo-for-peo."},{"issue":"8","key":"1365_CR98","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et\u00a0al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"1","key":"1365_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et\u00a0al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"key":"1365_CR100","unstructured":"Lee WK, Lai TYY, Tomohiro I, Chen S-J, Cheung G, Margaron P. Design and rationale of the SALWEEN trial: a phase 3b\/4 study of faricimab a dual angiopoietin-2 and vascular endothelial growth factor-a inhibitor, in patients with polypoidal choroidal vasculopathy. Presented at Asia-Pacific Vitreo-retina Society; 2022. Taipei, Taiwan."},{"issue":"1","key":"1365_CR101","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, et\u00a0al. One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14(1):11681.","journal-title":"Sci Rep"},{"issue":"1","key":"1365_CR102","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1):6759.","journal-title":"Sci Rep"},{"issue":"9","key":"1365_CR103","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/biomedicines9091164","volume":"9","author":"Y Fukuda","year":"2021","unstructured":"Fukuda Y, Sakurada Y, Matsubara M, et\u00a0al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines. 2021;9(9):1164.","journal-title":"Biomedicines"},{"issue":"3","key":"1365_CR104","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","volume":"65","author":"Y Ogura","year":"2021","unstructured":"Ogura Y, Iida T, Lee WK, et\u00a0al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study. Jpn J Ophthalmol. 2021;65(3):344\u201353.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1365_CR105","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1038\/s41598-022-12216-2","volume":"12","author":"A Ito","year":"2022","unstructured":"Ito A, Maruyama-Inoue M, Kitajima Y, Ikeda S, Inoue T, Kadonosono K. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. Sci Rep. 2022;12(1):7987.","journal-title":"Sci Rep"},{"issue":"4","key":"1365_CR106","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.4103\/ijo.IJO_2513_21","volume":"70","author":"D Chakraborty","year":"2022","unstructured":"Chakraborty D, Maiti A, Sengupta S, Mondal S, Nandi K, Chakraborty S. Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes\u2014A multicenter retrospective study. Indian J Ophthalmol. 2022;70(4):1295\u20139.","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"1365_CR107","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1167\/iovs.05-1229","volume":"47","author":"M Saint-Geniez","year":"2006","unstructured":"Saint-Geniez M, Maldonado AE, D\u2019Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47(7):3135\u201342.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1365_CR108","first-page":"1912","volume":"40","author":"A Otani","year":"1999","unstructured":"Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40(9):1912\u201320.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1365_CR109","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Leithner PL, Foxton R, et\u00a0al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1365_CR110","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, et\u00a0al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13(1):8747.","journal-title":"Sci Rep"},{"issue":"6","key":"1365_CR111","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","volume":"260","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro T, Tanaka K, Itagaki K, et\u00a0al. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1857\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1365_CR112","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, et\u00a0al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology. 2016;123(3):617\u201324.","journal-title":"Ophthalmology"},{"issue":"3","key":"1365_CR113","doi-asserted-by":"publisher","first-page":"474","DOI":"10.18240\/ijo.2022.03.16","volume":"15","author":"Z Huang","year":"2022","unstructured":"Huang Z, Deng KY, Deng YM, Hui YN, Song YP. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study. Int J Ophthalmol. 2022;15(3):474\u201382.","journal-title":"Int J Ophthalmol"},{"issue":"19","key":"1365_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195729","volume":"13","author":"T Sorrentino","year":"2024","unstructured":"Sorrentino T, Allegrini D, De Rosa G, et\u00a0al. Settings and clinical applications of subthreshold micropulse laser therapy: a review. J Clin Med. 2024;13(19):5729.","journal-title":"J Clin Med"},{"issue":"6","key":"1365_CR115","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00417-020-04702-y","volume":"258","author":"M Luo","year":"2020","unstructured":"Luo M, Zhao X, Yang J, Chen Y. The association of polypoidal choroidal vasculopathy clinical phenotypes with previously reported genetic markers. Graefes Arch Clin Exp Ophthalmol. 2020;258(6):1199\u2013203.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"1365_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111335","volume":"11","author":"X D\u00edaz-Villamar\u00edn","year":"2020","unstructured":"D\u00edaz-Villamar\u00edn X, Bl\u00e1nquez-Mart\u00ednez D, Pozo-Agundo A, et\u00a0al. Genetic variants affecting anti-VEGF drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis. Genes. 2020;11(11):1335.","journal-title":"Genes"},{"issue":"18","key":"1365_CR117","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41433-023-02610-z","volume":"37","author":"S Chandra","year":"2023","unstructured":"Chandra S, Tan EY, Empeslidis T, Sivaprasad S. Tyrosine kinase inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2023;37(18):3725\u201333.","journal-title":"Eye"},{"issue":"8","key":"1365_CR118","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1021\/acsmedchemlett.7b00253","volume":"8","author":"AF Abdel-Magid","year":"2017","unstructured":"Abdel-Magid AF. Plasma kallikrein inhibitors for the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. ACS Med Chem Lett. 2017;8(8):776\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"1365_CR119","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/bjophthalmol-2020-315817","volume":"105","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang W, Yang J, et\u00a0al. Automated diagnoses of age-related macular degeneration and polypoidal choroidal vasculopathy using bi-modal deep convolutional neural networks. Br J Ophthalmol. 2021;105(4):561\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1365_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86526-2","volume":"11","author":"YB Chou","year":"2021","unstructured":"Chou YB, Hsu CH, Chen WS, et\u00a0al. Deep learning and ensemble stacking technique for differentiating polypoidal choroidal vasculopathy from neovascular age-related macular degeneration. Sci Rep. 2021;11(1):7130.","journal-title":"Sci Rep"},{"issue":"2","key":"1365_CR121","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ophtha.2022.09.013","volume":"130","author":"Q Bo","year":"2023","unstructured":"Bo Q, Zhang M, Chen J, et\u00a0al. Progression of polypoidal lesions associated with exudative recurrence in polypoidal choroidal vasculopathy. Ophthalmology. 2023;130(2):167\u201378.","journal-title":"Ophthalmology"},{"key":"1365_CR122","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajo.2020.05.017","volume":"217","author":"K Kim","year":"2020","unstructured":"Kim K, Yang J, Feuer W, et\u00a0al. A comparison study of polypoidal choroidal vasculopathy imaged with indocyanine green angiography and swept-source optical coherence tomography angiography. Am J Ophthalmol. 2020;217:240\u201351.","journal-title":"Am J Ophthalmol"},{"key":"1365_CR123","unstructured":"Le PH, Kaur K, Patel BC. Optical coherence tomography angiography. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563235\/. Accessed 15 Nov 2025."},{"issue":"6","key":"1365_CR124","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.6.6.4","volume":"6","author":"CB Rebhun","year":"2017","unstructured":"Rebhun CB, Moult EM, Novais EA, et\u00a0al. Polypoidal choroidal vasculopathy on swept-source optical coherence tomography angiography with variable interscan time analysis. Transl Vis Sci Technol. 2017;6(6):4.","journal-title":"Transl Vis Sci Technol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01365-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01365-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01365-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:02:24Z","timestamp":1778756544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01365-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01365-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Boehringer Ingelheim was given the opportunity to review the article for medical and scientific accuracy and intellectual property considerations. Adrian Koh declares support from AbbVie, Apellis Pharmaceuticals, Astellas, Bayer Healthcare Pharmaceuticals, Boehringer Mannheim, Carl Zeiss Meditec, Heidelberg Engineering, Nikon, Novartis Pharmaceuticals, Roche,\u00a0and Topcon. Giovanni Staurenghi has consulted for, or advised, AbbVie, Annexon Biosciences, Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Genentech, Heidelberg Engineering, Hoffmann-La Roche Ltd., Iveric Bio, Medscape, Novartis Pharmaceuticals, Optos, Inc., and RetinAI; has received speaker fees from Carl Zeiss Meditec, CenterVue, Inc., Heidelberg Engineering, Hoffmann-La Roche Ltd., Medscape, Nidek, Inc., and Novartis Pharmaceuticals; has received grant support from Carl Zeiss Meditec, CenterVue, Inc., Heidelberg Engineering, Hoffmann-La Roche Ltd., Nidek, Inc., Novartis Pharmaceuticals, Optos, Inc., and RetinAI; and has received royalties from Ocular Instruments, Inc. Jay Chhablani has consulted for Allergan, Bausch\u2009+\u2009Lomb, Erasca, EyePoint, Iveric\u00a0Bio, Novartis Pharmaceuticals, OD-OS, and Salutaris. Georgios D. Panos has received travel grants and honoraria from Roche, Bayer, and Th\u00e9a. Colin S. Tan has received honoraria from Astellas, Bayer Healthcare Pharmaceuticals, and Roche. Taffeta Ching Ning Yamaguchi is an employee of Boehringer Ingelheim. Theo Empeslidis was an employee of Boehringer Ingelheim when the manuscript was developed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}